Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks

OCT, Visual Outcome and Angiographic Analysis of Choroidal Neovascularization in Six Eyes With Angioid Streaks Treated With a Single Intravitreal Injection of Bevacizumab

Intravitreal Bevacizumab is an effective treatment for choroidal neovascularization secondary to Angioid Streaks

A consecutive case series of patients with angioid streaks that developed subfoveal choroidal neovascularization were treated with a primary 2.5 mg injection of Bevacizumab (Avastin) intravitreally. All patients were evaluated with BCVA at 1, 2 , 4 and 12 weeks and OCT and fluoresceine angiography at month 1 and 3. (Patients will be follow 6 months)

Inclusion Criteria:

• Clinical diagnosis of Angioid Streaks
• Choroidal neovascularization associated
• Untreated patients or patients treated once with PDT

Exclusion Criteria:

• Ocular surgery excepting uncomplicated phacoemulsification
• Glaucoma or any other ocular pathology